This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Allergan Settles Ahead of Multi-District Opioid Litigation
by Zacks Equity Research
Allergan (AGN) settles with two counties of Ohio for $5 million related to the upcoming multidistrict litigation for opioid-based drug abuse.
Novartis' (NVS) MS Drug Achieves Goals in Late-Stage Studies
by Zacks Equity Research
Novartis (NVS) MS drug meets primary and secondary endpoints in late-stage studies.
Will Opioid Litigation Take its Toll on Pharma Companies?
by Indrajit Bandyopadhyay
Thousands of pending opioid-abuse lawsuits against several pharma companies come into limelight after the Oklahoma ruling against J&J. Let's see what's in store for these companies.
J&J (JNJ) Loses Landmark Opioid Case: What's Next for Pharmaceuticals?
by Christopher Vargas
An Oklahoma judge ruled on Monday that large cap pharmaceutical company Johnson & Johnson (JNJ) would have to pay $572 million to the state.
AstraZeneca's Fasenra Gets Orphan Drug Status for New Disease
by Zacks Equity Research
AstraZeneca's (AZN) Fasenra gets Orphan Drug status for eosinophilic oesophagitis (EoE). A phase III COPD study on Breztri Aerosphere meets primary endpoint.
J&J Up Despite $572M Fine in Oklahoma Opioid Abuse Case
by Zacks Equity Research
A court ordered J&J (JNJ) to pay $527 million in the Oklahoma litigation related to abuse of its opioid-based drugs. The company is facing similar litigation in multiple states.
Case-Shiller Index Nudges Up
by Zacks Equity Research
Case-Shiller Index Nudges Up
J&J to Pay $572M in Opioid Case; Plus Case-Shiller Home Price Read
by Mark Vickery
Johnson & Johnson (JNJ) now owes $572 million, as per the judge in this case, which pits J&J responsible for rampant opioid use.
J&J's (JNJ) Opioid Lawsuit Verdict in Oklahoma Due Next Week
by Zacks Equity Research
J&J (JNJ) is facing several litigation in multiple states related to abuse of its opioid-based drugs. A ruling is expected on Aug 26 in a trial filed by the state of Oklahoma.
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
by Kinjel Shah
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA
by Zacks Equity Research
The FDA grants priority review to BeiGene's (BGNE) NDA seeking approval for zanubrutinib as a treatment for mantle cell lymphoma.
Mallinckrodt (MNK) Stock Down 70.8% YTD on Numerous Lawsuits
by Zacks Equity Research
Mallinckrodt (MNK) crashes 70.8% in the year so far due to various lawsuits and litigations.
Endo Up on Settlement of a Few Cases Related to Opioid Drugs
by Zacks Equity Research
Endo (ENDP) finally has some good news for investors with the settlement of a few cases in Ohio related to opioid medications.
Teva Launches Generic Version of Mylan's EpiPen for KIds
by Zacks Equity Research
Teva (TEVA) launches generic version of Mylan's (MYL) popular EpiPen Jr allergy treatment at a price of $300 for a pack of two.
Should Value Investors Pick Teva Pharmaceutical (TEVA) Now?
by Zacks Equity Research
Let's see if Teva Pharmaceutical (TEVA) stock is a good choice for value-oriented investors right now from multiple angles.
Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
by Zacks Equity Research
Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.
BioDelivery (BDSI) Earnings & Sales Beat Estimates in Q2
by Zacks Equity Research
BioDelivery (BDSI) reports earnings against expectations of loss in Q2 and raises guidance for 2019.
Teva (TEVA) Q2 Earnings, Sales Top Estimates, CFO Steps Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) posts better-than-expected results. However, earnings and sales decline year over year.
Teva (TEVA) Beats Q2 Earnings & Sales Estimates, Shares Rise
by Kinjel Shah
Teva Pharmaceutical (TEVA) posts better-than-expected results. Shares rise in pre-market trading.
Cronos (CRON) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on Cronos' (CRON) regular top and bottom-line numbers along with its pipeline progress when it reports second-quarter results.
Will Cost Control Help Teva (TEVA) Beat on Q2 Earnings?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q2.
Amgen (AMGN) Q2 Earnings & Sales Beat, New Drugs Shine
by Zacks Equity Research
Amgen (AMGN) beats estimates for earnings and sales in the second quarter. Higher demand for new growth drivers was offset by the erosion of mature brands from brand/biosimilar competition.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $7.91 in the latest trading session, marking a +0.64% move from the prior day.
Lilly (LLY) Q2 Earnings Beat, New Drugs Drive Sales, Stock Up
by Zacks Equity Research
Eli Lilly's (LLY) Q2 earnings beat estimates while sales miss. New drugs drive sales despite generic competition to key drug Cialis.
Mylan (MYL) Beats on Q2 Earnings, Inks Deal with Pfizer
by Zacks Equity Research
Mylan (MYL) gains from merger deal with a Pfizer unit and tops on earnings and sales in Q2.